Cargando…

Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study

BACKGROUND: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. AIMS: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) METHODS: Effectiveness and Safety of COVID-19 Vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Macaluso, Fabio Salvatore, Principi, Mariabeatrice, Facciotti, Federica, Contaldo, Antonella, Todeschini, Alessia, Saibeni, Simone, Bezzio, Cristina, Castiglione, Fabiana, Nardone, Olga Maria, Spagnuolo, Rocco, Fantini, Massimo Claudio, Riguccio, Gaia, Caprioli, Flavio, Viganò, Chiara, Felice, Carla, Fiorino, Gionata, Correale, Carmen, Bodini, Giorgia, Milla, Monica, Scardino, Giulia, Vernero, Marta, Desideri, Federico, Mannino, Mariella, Rizzo, Giuseppe, Orlando, Ambrogio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420701/
https://www.ncbi.nlm.nih.gov/pubmed/36127228
http://dx.doi.org/10.1016/j.dld.2022.08.027
_version_ 1784777446862618624
author Macaluso, Fabio Salvatore
Principi, Mariabeatrice
Facciotti, Federica
Contaldo, Antonella
Todeschini, Alessia
Saibeni, Simone
Bezzio, Cristina
Castiglione, Fabiana
Nardone, Olga Maria
Spagnuolo, Rocco
Fantini, Massimo Claudio
Riguccio, Gaia
Caprioli, Flavio
Viganò, Chiara
Felice, Carla
Fiorino, Gionata
Correale, Carmen
Bodini, Giorgia
Milla, Monica
Scardino, Giulia
Vernero, Marta
Desideri, Federico
Mannino, Mariella
Rizzo, Giuseppe
Orlando, Ambrogio
author_facet Macaluso, Fabio Salvatore
Principi, Mariabeatrice
Facciotti, Federica
Contaldo, Antonella
Todeschini, Alessia
Saibeni, Simone
Bezzio, Cristina
Castiglione, Fabiana
Nardone, Olga Maria
Spagnuolo, Rocco
Fantini, Massimo Claudio
Riguccio, Gaia
Caprioli, Flavio
Viganò, Chiara
Felice, Carla
Fiorino, Gionata
Correale, Carmen
Bodini, Giorgia
Milla, Monica
Scardino, Giulia
Vernero, Marta
Desideri, Federico
Mannino, Mariella
Rizzo, Giuseppe
Orlando, Ambrogio
author_sort Macaluso, Fabio Salvatore
collection PubMed
description BACKGROUND: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. AIMS: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) METHODS: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs). RESULTS: 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reported for most IBD patients, even if with a lesser rate compared with HCs (92.1% vs. 97.9%; p<0.001). HCs had higher antibody concentrations (median OD 8.72 [IQR 5.2-14-2]) compared to the whole cohort of IBD patients (median OD 1.54 [IQR 0.8-3.6]; p<0.001) and the subgroup of IBD patients (n=280) without any treatment or on aminosalicylates only (median OD 1.72 [IQR 1.0–4.1]; p<0.001). CONCLUSIONS: Although most IBD patients showed seropositivity after COVID-19 vaccines, the magnitude of the humoral response was significantly lower than in HCs. Differently from other studies, these findings seem to be mostly unrelated to the use of immune-modifying treatments (ClinicalTrials.govID:NCT04769258).
format Online
Article
Text
id pubmed-9420701
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-94207012022-08-30 Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study Macaluso, Fabio Salvatore Principi, Mariabeatrice Facciotti, Federica Contaldo, Antonella Todeschini, Alessia Saibeni, Simone Bezzio, Cristina Castiglione, Fabiana Nardone, Olga Maria Spagnuolo, Rocco Fantini, Massimo Claudio Riguccio, Gaia Caprioli, Flavio Viganò, Chiara Felice, Carla Fiorino, Gionata Correale, Carmen Bodini, Giorgia Milla, Monica Scardino, Giulia Vernero, Marta Desideri, Federico Mannino, Mariella Rizzo, Giuseppe Orlando, Ambrogio Dig Liver Dis Alimentary Tract BACKGROUND: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. AIMS: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) METHODS: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs). RESULTS: 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reported for most IBD patients, even if with a lesser rate compared with HCs (92.1% vs. 97.9%; p<0.001). HCs had higher antibody concentrations (median OD 8.72 [IQR 5.2-14-2]) compared to the whole cohort of IBD patients (median OD 1.54 [IQR 0.8-3.6]; p<0.001) and the subgroup of IBD patients (n=280) without any treatment or on aminosalicylates only (median OD 1.72 [IQR 1.0–4.1]; p<0.001). CONCLUSIONS: Although most IBD patients showed seropositivity after COVID-19 vaccines, the magnitude of the humoral response was significantly lower than in HCs. Differently from other studies, these findings seem to be mostly unrelated to the use of immune-modifying treatments (ClinicalTrials.govID:NCT04769258). Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2023-02 2022-08-29 /pmc/articles/PMC9420701/ /pubmed/36127228 http://dx.doi.org/10.1016/j.dld.2022.08.027 Text en © 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Alimentary Tract
Macaluso, Fabio Salvatore
Principi, Mariabeatrice
Facciotti, Federica
Contaldo, Antonella
Todeschini, Alessia
Saibeni, Simone
Bezzio, Cristina
Castiglione, Fabiana
Nardone, Olga Maria
Spagnuolo, Rocco
Fantini, Massimo Claudio
Riguccio, Gaia
Caprioli, Flavio
Viganò, Chiara
Felice, Carla
Fiorino, Gionata
Correale, Carmen
Bodini, Giorgia
Milla, Monica
Scardino, Giulia
Vernero, Marta
Desideri, Federico
Mannino, Mariella
Rizzo, Giuseppe
Orlando, Ambrogio
Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
title Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
title_full Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
title_fullStr Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
title_full_unstemmed Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
title_short Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
title_sort reduced humoral response to two doses of covid-19 vaccine in patients with inflammatory bowel disease: data from escape-ibd, an ig-ibd study
topic Alimentary Tract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420701/
https://www.ncbi.nlm.nih.gov/pubmed/36127228
http://dx.doi.org/10.1016/j.dld.2022.08.027
work_keys_str_mv AT macalusofabiosalvatore reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT principimariabeatrice reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT facciottifederica reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT contaldoantonella reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT todeschinialessia reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT saibenisimone reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT bezziocristina reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT castiglionefabiana reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT nardoneolgamaria reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT spagnuolorocco reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT fantinimassimoclaudio reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT rigucciogaia reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT caprioliflavio reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT viganochiara reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT felicecarla reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT fiorinogionata reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT correalecarmen reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT bodinigiorgia reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT millamonica reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT scardinogiulia reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT verneromarta reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT desiderifederico reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT manninomariella reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT rizzogiuseppe reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT orlandoambrogio reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy
AT reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy